Prewett E J, Luk Y W, Fraser A G, Lam W M, Pounder R E
University Department of Medicine, Royal Free Hospital School of Medicine, London, UK.
Aliment Pharmacol Ther. 1992 Feb;6(1):97-102. doi: 10.1111/j.1365-2036.1992.tb00549.x.
Assessment of intragastric urease activity by the 13C-urea breath test was performed before and after one day of dosing with either De-Noltabs (tripotassium dicitrato bismuthate, one tablet 1 q.d.s.), Pepto-Bismol liquid (bismuth salicylate 30 ml q.d.s.), or Roter tablets (bismuth subnitrate, one tablet q.d.s.) in twelve Helicobacter pylori-positive patient volunteers. There was a significant decrease in the excess of 13CO2 after one day of dosing with each of the three bismuth compounds, but analysis of variance could detect no difference between the effects of the three compounds. Systemic absorption of bismuth following oral dosing with either Pepto-Bismol or Roter is minimal, yet both compounds have a suppressive effect on H. pylori similar to that of De-Noltab. This study suggests that the action of all three bismuth compounds is within the gastric lumen, and that systemic absorption of bismuth is not necessary for activity against H. pylori.
在12名幽门螺杆菌阳性的患者志愿者中,在服用De-Noltabs(枸橼酸铋钾,每日4次,每次1片)、Pepto-Bismol液剂(碱式水杨酸铋,每日4次,每次30 ml)或Roter片(碱式硝酸铋,每日4次,每次1片)一天前后,通过¹³C尿素呼气试验评估胃内脲酶活性。服用这三种铋化合物中的任何一种一天后,¹³CO₂过量均显著降低,但方差分析未发现这三种化合物的效果有差异。口服Pepto-Bismol或Roter后铋的全身吸收极少,但这两种化合物对幽门螺杆菌的抑制作用与De-Noltab相似。本研究表明,所有三种铋化合物的作用均在胃腔内,并且铋的全身吸收对于抗幽门螺杆菌活性并非必需。